Novel fgfr3 inhibitor compounds
By providing novel FGFR3 inhibitor compounds, the problem of lacking highly specific and low-side-effect FGFR3 inhibitors in the prior art has been solved, enabling effective treatment of FGFR3-related diseases and providing new treatment strategies and methods.
CN122255133APending Publication Date: 2026-06-23SHANGHAI HUIKE BIOPHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI HUIKE BIOPHARMACEUTICAL CO LTD
- Filing Date
- 2025-06-11
- Publication Date
- 2026-06-23
Smart Images
Figure CN122255133A_ABST
Abstract
The present invention relates to structurally novel FGFR3 inhibitor compounds or pharmaceutically acceptable salts, isotopologues, tautomers, stereoisomers or prodrugs thereof, and their use as medicaments. The compounds can be used for the treatment of cancer such as urothelial cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delays and acanthocytosis or Muenke syndrome.
Need to check novelty before this filing date? Find Prior Art